Interim Results for six months ended 31 Dec 2025

AI SummaryClose X

Allergy Therapeutics plc reported interim revenues of £36.3 million for the six months ended December 31, 2025, a 7% increase from the prior year, driven by the regulatory approval and commercial launch of Grassmuno® in Germany. The company's short-course peanut allergy vaccine candidate, VLP Peanut, met its Phase I/IIa primary endpoint, with Phase IIb planning underway. Financially, the company strengthened its balance sheet and secured a new £40 million senior secured facility post-period end, while continuing to explore a dual primary listing on the Hong Kong Stock Exchange. The operating loss before R&D was £2.5 million, compared to a £1.9 million operating profit in the prior period, reflecting strategic investments.

Disclaimer*

UK 100

Latest directors dealings